Molecularly-targeted Strategy and NF-κB in lymphoid malignancies.
J Clin Exp Hematop
; 53(3): 185-95, 2013.
Article
en En
| MEDLINE
| ID: mdl-24369220
Molecularly-targeted therapy is a promising strategy for the treatment of cancer. Nuclear factor (NF)-κB is a transcription factor that is constitutively activated in various lymphoid malignancies and may therefore be a good therapeutic target. Lymphoid malignancies arise from different stages of normal lymphocyte differentiation and acquire distinct pathways for constitutive NF-κB activation. However, no NF-κB inhibitor has yet been successfully applied in clinical medicine. This review focuses on the concept of molecularly-targeted therapeutics with small molecule drugs, molecular mechanisms of constitutive NF-κB activation in lymphoid malignancies, and the development of NF-κB inhibitors. A future perspective regarding the development of NF-κB inhibitors is also included.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Leucemia Linfoide
/
FN-kappa B
/
Terapia Molecular Dirigida
/
Linfoma
Tipo de estudio:
Diagnostic_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
J Clin Exp Hematop
Asunto de la revista:
HEMATOLOGIA
/
PATOLOGIA
Año:
2013
Tipo del documento:
Article
Pais de publicación:
Japón